Meningitis neumocócica en niños españoles: incidencia, serotipos y resistencia antibiótica. Estudio prospectivo multicéntrico

Flores, J. Casado; Fenoll, Asunción; Berrón, S.; Fernández, Julio Blanco; Liria, C. Rodrigo de; Sánchez, J.M. Martinón; Pérez, Cristina Fernández

doi:10.1016/s1695-4033(02)77930-7

Cited by 34 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…En periodos previos a la vacuna o cuando todavía ésta estaba poco implantada, las tasas de incidencia oscilaban entre 31 y 59 casos por 100.000 niños menores de 5 años. Las tasas de meningitis neumocócica en este mismo grupo de edad oscilaron entre 0,9 y 5,6 casos por 100.000 niños [75][76][77][78] . Estos estudios están sujetos a algunas limitaciones, ya que no siempre tienen base poblacional bien establecida, la mayoría fueron realizados de forma retrospectiva y se desconoce la sistemática de petición de hemocultivos.…”

Section: Incidenciaunclassified

“…Esta tasa era próxima a la que se describía en los Estados Unidos antes de que se introdujese la VNC7v 80 , y en general más alta que la encontrada en otros estudios en Europa y en España (Tabla 1) 9,75-77,79,81-98 . El porcentaje de bacteriemias ocultas en Navarra es similar o superior al descrito en otros lugares, lo que parece indicar que la exhaustividad del sistema de vigilancia es equiparable o mayor a la de dichos estudios [76][77][78]88 , y vendría a explicar, al menos en parte, el exceso de incidencia de ENI en Navarra 79 .…”

Section: Incidenciaunclassified

See 1 more Smart Citation

La vacuna neumocócica conjugada heptavalente (Prevenar™): Diferencias en su efectividad en distintas poblaciones

Guevara

Barricarte

Pérez

et al. 2008

Anales Sis San Navarra

View full text Add to dashboard Cite

Section: Incidenciaunclassified

La vacuna neumocócica conjugada heptavalente (Prevenar™): Diferencias en su efectividad en distintas poblaciones

Guevara

Barricarte

Pérez

et al. 2008

Anales Sis San Navarra

View full text Add to dashboard Cite

Clinical data and factors associated with poor outcome in pneumococcal meningitis

Casado‐Flores

Corrêa-Oliveira

et al. 2005

Eur J Pediatr

View full text Add to dashboard Cite

We carried out a 4-year study of 159 children (ages 1 month-14 years) with pneumococcal meningitis. The study was divided into two periods: the retrospective period (1998-2000: 107 patients), and the prospective period (2001-2002: 52 patients). About 2/3 of the children were under 2 years of age: 72 (45%) were under 1 year of age and 38 (24%) had meningitis during the second year of life. One-third of the patients had signs of otitis media; convulsions were more frequent in patients under 1 year compared with older patients (34.7 vs. 14.9%; P=0.004); 13/159 children (8.2%) died; 93/159 (58.5%) recovered completely, 12.6% had motor sequelae, 6.9% hydrocephalus, 29.8% sensorineural hearing loss; 140/159 (88%) were treated with third generation cephalosporins, yet only 8.7% of the pneumococci identified were completely penicillin-resistant (> or =1 microg/ml); 119/159 were treated with dexamethasone. Four patients had received an injection of heptavalent vaccine. Antibiotics for 1 week prior to admission, shock, abnormal pupils, leukocytes count <6,000 mm(3), and CSF glucose < or =8.5 mg/dl were significantly associated with poor outcome and/or death in the univariate analysis. No patient with leukocytosis >16,000/mm(3) died. Conclusion. Sequelae are very common in pneumococcal meningitis. Poor outcome was associated with pupillary abnormality and a leukocyte count <6,000/mm(3) on admission. Leukocytosis was protective against poor outcome.

show abstract

Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine

Bernaola

Pocheville

et al. 2007

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

This study evaluated the incidence of invasive pneumococcal disease, identified the causal serotypes, and tracked the evolution of the antibiotic susceptibility of Streptococcus pneumoniae isolates in the regions of the Basque Country and Navarre, Spain, before and after the introduction of the heptavalent pneumococcal conjugate vaccine. The study included all children aged between birth and 5 years diagnosed with bacteremia, meningitis, or bacteremic pneumonia caused by pneumococci. By the second year after introduction of the heptavalent pneumococcal conjugate vaccine, compared with the period 1998-2001, the incidence of invasive disease decreased by 64.3% in children less than 12 months of age, by 39.7% in children less than 24 months of age, and by 37.5% in children less than 60 months of age. The prevalence of clinical isolates of S. pneumoniae that lacked susceptibility to penicillin decreased by 58.2% among children less than 60 months of age. With an estimated coverage by four-dose heptavalent pneumococcal conjugate vaccine of 28-45% in 2003, the number of invasive pneumococcal infections in the Basque Country and in Navarre fell significantly after just 2 years of immunization, underscoring the importance of improving vaccination coverage under a universal childhood immunization program.

show abstract

Meningitis neumocócica en niños españoles: incidencia, serotipos y resistencia antibiótica. Estudio prospectivo multicéntrico

Cited by 34 publications

References 15 publications

La vacuna neumocócica conjugada heptavalente (Prevenar™): Diferencias en su efectividad en distintas poblaciones

La vacuna neumocócica conjugada heptavalente (Prevenar™): Diferencias en su efectividad en distintas poblaciones

Clinical data and factors associated with poor outcome in pneumococcal meningitis

Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine

Contact Info

Product

Resources

About

Meningitis neumocócica en niños españoles: incidencia, serotipos y resistencia antibiótica. Estudio prospectivo multicéntrico

Cited by 34 publications

References 15 publications

La vacuna neumocócica conjugada heptavalente (Prevenar&trade;): Diferencias en su efectividad en distintas poblaciones

La vacuna neumocócica conjugada heptavalente (Prevenar&trade;): Diferencias en su efectividad en distintas poblaciones

Clinical data and factors associated with poor outcome in pneumococcal meningitis

Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine

Contact Info

Product

Resources

About

La vacuna neumocócica conjugada heptavalente (Prevenar™): Diferencias en su efectividad en distintas poblaciones

La vacuna neumocócica conjugada heptavalente (Prevenar™): Diferencias en su efectividad en distintas poblaciones